Related references
Note: Only part of the references are listed.Tumor Microenvironment Versus Cancer Stem Cells in Cholangiocarcinoma: Synergistic Effects?
Maurizio Romano et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
Marcela V. Maus et al.
CLINICAL CANCER RESEARCH (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Hanren Dai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Michael B. Bernstein et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps
Gregory L. Beatty et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
Kaichao Feng et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
CD133, Selectively Targeting the Root of Cancer
Jorg U. Schmohl et al.
TOXINS (2016)
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Hanren Dai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Immune-priming of the Tumor Microenvironment by Radiotherapy Rationale for Combination With Immunotherapy to Improve Anticancer Efficacy
Vafa Shahabi et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2015)
Epidemiology of cholangiocarcinoma
Annika Bergquist et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2015)
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
Hillary G. Caruso et al.
CANCER RESEARCH (2015)
Targeted Therapy in Biliary Tract Cancers
Amartej Merla et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)
Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure
Concetta Elisa Onesti et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial
Encouse B. Golden et al.
LANCET ONCOLOGY (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
Hanren Dai et al.
ONCOIMMUNOLOGY (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2014)
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
David Malka et al.
LANCET ONCOLOGY (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
James N. Kochenderfer et al.
BLOOD (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells
Brian J. Cameron et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
Liza B. John et al.
ONCOIMMUNOLOGY (2013)
Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer
Asis Palazon et al.
CLINICAL CANCER RESEARCH (2012)
Recent advances in cancer stem cell research for cholangiocarcinoma
Toshio Kokuryo et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2012)
Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy
Kazuhiko Shien et al.
LUNG CANCER (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
Strong expression of CD133 is associated with increased cholangiocarcinoma progression
Kawin Leelawat et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia
Lisa McGinley et al.
STEM CELL RESEARCH & THERAPY (2011)
Share Paper
